PMC:7105881 / 26121-26688 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"893","span":{"begin":503,"end":506},"obj":"Gene"},{"id":"922","span":{"begin":560,"end":563},"obj":"Gene"},{"id":"923","span":{"begin":383,"end":391},"obj":"Species"},{"id":"924","span":{"begin":458,"end":466},"obj":"Species"},{"id":"925","span":{"begin":527,"end":531},"obj":"Species"},{"id":"926","span":{"begin":540,"end":548},"obj":"Species"},{"id":"1000","span":{"begin":435,"end":439},"obj":"CellLine"}],"attributes":[{"id":"A893","pred":"tao:has_database_id","subj":"893","obj":"Gene:4352"},{"id":"A922","pred":"tao:has_database_id","subj":"922","obj":"Gene:51428"},{"id":"A923","pred":"tao:has_database_id","subj":"923","obj":"Tax:694009"},{"id":"A924","pred":"tao:has_database_id","subj":"924","obj":"Tax:694009"},{"id":"A925","pred":"tao:has_database_id","subj":"925","obj":"Tax:10090"},{"id":"A926","pred":"tao:has_database_id","subj":"926","obj":"Tax:694009"},{"id":"A1000","pred":"tao:has_database_id","subj":"1000","obj":"CVCL:5V07"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antibody response Cellular immune response Protection References\nSubunit vaccines based on SARS-CoV full-length or trimeric S protein\nFL-S and EC-S proteins Bind to SARS-CoV S1, NTD, RBD, and S2-specific mAbs MPL + TDM S.C. BALB/c mice Elicit SARS-CoV S-specific Abs (Ig"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T114","span":{"begin":81,"end":88},"obj":"Body_part"},{"id":"T115","span":{"begin":289,"end":297},"obj":"Body_part"},{"id":"T116","span":{"begin":418,"end":425},"obj":"Body_part"},{"id":"T117","span":{"begin":440,"end":448},"obj":"Body_part"}],"attributes":[{"id":"A114","pred":"fma_id","subj":"T114","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A115","pred":"fma_id","subj":"T115","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A116","pred":"fma_id","subj":"T116","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A117","pred":"fma_id","subj":"T117","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":" have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antibody response Cellular immune response Protection References\nSubunit vaccines based on SARS-CoV full-length or trimeric S protein\nFL-S and EC-S proteins Bind to SARS-CoV S1, NTD, RBD, and S2-specific mAbs MPL + TDM S.C. BALB/c mice Elicit SARS-CoV S-specific Abs (Ig"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T113","span":{"begin":43,"end":47},"obj":"Disease"},{"id":"T114","span":{"begin":208,"end":212},"obj":"Disease"},{"id":"T115","span":{"begin":383,"end":391},"obj":"Disease"},{"id":"T116","span":{"begin":458,"end":466},"obj":"Disease"},{"id":"T117","span":{"begin":471,"end":474},"obj":"Disease"},{"id":"T119","span":{"begin":540,"end":548},"obj":"Disease"}],"attributes":[{"id":"A113","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A114","pred":"mondo_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A115","pred":"mondo_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A116","pred":"mondo_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A117","pred":"mondo_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/MONDO_0008449"},{"id":"A118","pred":"mondo_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/MONDO_0018075"},{"id":"A119","pred":"mondo_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":" have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antibody response Cellular immune response Protection References\nSubunit vaccines based on SARS-CoV full-length or trimeric S protein\nFL-S and EC-S proteins Bind to SARS-CoV S1, NTD, RBD, and S2-specific mAbs MPL + TDM S.C. BALB/c mice Elicit SARS-CoV S-specific Abs (Ig"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T274","span":{"begin":274,"end":280},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"},{"id":"T275","span":{"begin":426,"end":428},"obj":"http://purl.obolibrary.org/obo/CLO_0003358"},{"id":"T276","span":{"begin":435,"end":437},"obj":"http://purl.obolibrary.org/obo/CLO_0002878"},{"id":"T277","span":{"begin":467,"end":469},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T278","span":{"begin":485,"end":487},"obj":"http://purl.obolibrary.org/obo/CLO_0008922"},{"id":"T279","span":{"begin":485,"end":487},"obj":"http://purl.obolibrary.org/obo/CLO_0050052"}],"text":" have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antibody response Cellular immune response Protection References\nSubunit vaccines based on SARS-CoV full-length or trimeric S protein\nFL-S and EC-S proteins Bind to SARS-CoV S1, NTD, RBD, and S2-specific mAbs MPL + TDM S.C. BALB/c mice Elicit SARS-CoV S-specific Abs (Ig"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T120","span":{"begin":81,"end":88},"obj":"Chemical"},{"id":"T121","span":{"begin":418,"end":425},"obj":"Chemical"},{"id":"T122","span":{"begin":426,"end":428},"obj":"Chemical"},{"id":"T123","span":{"begin":440,"end":448},"obj":"Chemical"},{"id":"T124","span":{"begin":485,"end":487},"obj":"Chemical"}],"attributes":[{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A121","pred":"chebi_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A122","pred":"chebi_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/CHEBI_91150"},{"id":"A123","pred":"chebi_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A124","pred":"chebi_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/CHEBI_29387"}],"text":" have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antibody response Cellular immune response Protection References\nSubunit vaccines based on SARS-CoV full-length or trimeric S protein\nFL-S and EC-S proteins Bind to SARS-CoV S1, NTD, RBD, and S2-specific mAbs MPL + TDM S.C. BALB/c mice Elicit SARS-CoV S-specific Abs (Ig"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T46","span":{"begin":308,"end":332},"obj":"http://purl.obolibrary.org/obo/GO_0002456"},{"id":"T47","span":{"begin":308,"end":332},"obj":"http://purl.obolibrary.org/obo/GO_0002449"},{"id":"T48","span":{"begin":308,"end":332},"obj":"http://purl.obolibrary.org/obo/GO_0002443"},{"id":"T49","span":{"begin":317,"end":332},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":" have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antibody response Cellular immune response Protection References\nSubunit vaccines based on SARS-CoV full-length or trimeric S protein\nFL-S and EC-S proteins Bind to SARS-CoV S1, NTD, RBD, and S2-specific mAbs MPL + TDM S.C. BALB/c mice Elicit SARS-CoV S-specific Abs (Ig"}

{"project":"LitCovid-sentences","denotations":[{"id":"T157","span":{"begin":174,"end":218},"obj":"Sentence"},{"id":"T158","span":{"begin":219,"end":356},"obj":"Sentence"},{"id":"T159","span":{"begin":357,"end":425},"obj":"Sentence"},{"id":"T160","span":{"begin":426,"end":518},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antibody response Cellular immune response Protection References\nSubunit vaccines based on SARS-CoV full-length or trimeric S protein\nFL-S and EC-S proteins Bind to SARS-CoV S1, NTD, RBD, and S2-specific mAbs MPL + TDM S.C. BALB/c mice Elicit SARS-CoV S-specific Abs (Ig"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T507","span":{"begin":43,"end":47},"obj":"SP_10"},{"id":"T508","span":{"begin":79,"end":88},"obj":"PG_1"},{"id":"T509","span":{"begin":100,"end":109},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T510","span":{"begin":208,"end":212},"obj":"SP_10"},{"id":"T35137","span":{"begin":43,"end":47},"obj":"SP_10"},{"id":"T98807","span":{"begin":79,"end":88},"obj":"PG_1"},{"id":"T16034","span":{"begin":100,"end":109},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T88526","span":{"begin":208,"end":212},"obj":"SP_10"}],"text":" have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).\nTABLE 1 Subunit Vaccines against SARS-CoVa.\nName Antigenicity and functionality Adjuvant Route Animal models Antibody response Cellular immune response Protection References\nSubunit vaccines based on SARS-CoV full-length or trimeric S protein\nFL-S and EC-S proteins Bind to SARS-CoV S1, NTD, RBD, and S2-specific mAbs MPL + TDM S.C. BALB/c mice Elicit SARS-CoV S-specific Abs (Ig"}